Brokers Suggest Investing in Viking Therapeutics (VKTX): Read This Before Placing a Bet
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?
Viking Therapeutics, Inc. (VKTX) Stock Drops Despite Market Gains: Important Facts to Note
In the closing of the recent trading day, Viking Therapeutics, Inc. (VKTX) stood at $32.12, denoting a -9.32% move from the preceding trading day.
Here's How VKTX's Obesity Drug Is Moving Quickly Through Phase III
Viking Therapeutics' obesity drug VK2735 is racing through phase III, with one pivotal study fully enrolled just months after launch.
Viking Therapeutics, Inc. (VKTX) Sees a More Significant Dip Than Broader Market: Some Facts to Know
In the latest trading session, Viking Therapeutics, Inc. (VKTX) closed at $35.32, marking a -3.13% move from the previous day.
Viking Therapeutics' Swing Trade Potential Emerges - Competition/Dilution Risks Remain
VKTX remains a Buy for its cheap FY2030 EV/Sales valuations of 2.28x, the strong clinical trial results exceeding legacy players, and the potential GLP-1 monetization upon US FDA approval. The management has also prudently focused on the oral/subcutaneous VK2735 clinical trials, potentially stretching their balance sheet over the next two years of unprofitability before requiring any capital raises. Execution risks persist, due to VKTX's Phase 3 trial completion no earlier than 2027 and commercialization sometime in 2028, along with future dilution risks from negative cash flows.
Viking Therapeutics, Inc. (VKTX) Beats Stock Market Upswing: What Investors Need to Know
In the latest trading session, Viking Therapeutics, Inc. (VKTX) closed at $36.41, marking a +2.85% move from the previous day.
Wall Street Bulls Look Optimistic About Viking Therapeutics (VKTX): Should You Buy?
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?
Viking Therapeutics, Inc. (VKTX) Registers a Bigger Fall Than the Market: Important Facts to Note
Viking Therapeutics, Inc. (VKTX) closed at $36.15 in the latest trading session, marking a -2.51% move from the prior day.
Viking Therapeutics: Prepping For A Critical 2026
Viking Therapeutics is positioned for a pivotal 2026, advancing both injectable and oral VK2735 in obesity, with pipeline depth from an emerging amylin agonist program. VKTX's oral VK2735 has demonstrated unmatched double-digit weight loss in 13 weeks, potentially establishing leadership in the oral obesity drug segment. Despite a robust $714M cash position and a 4/5 conviction rating, risks include Phase III trial costs, competitive pressures, and potential dilution.
VKTX Stock Rises 34% in Three Months: Here's What You Should Know
Viking Therapeutics' shares jump 34% as rapid VK2735 trial enrollment boosts optimism amid intensifying interest in obesity treatments.
Wall Street Analysts Think Viking Therapeutics (VKTX) Is a Good Investment: Is It?
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?
Viking Therapeutics (VKTX) Up 1% Since Last Earnings Report: Can It Continue?
Viking Therapeutics (VKTX) reported earnings 30 days ago. What's next for the stock?
